As of late July 2025, Chemfab Alkalis Ltd is trading near ₹789 with recent price movements signaling some short-term recovery after a significant correction from the past year’s highs. The stock’s 52-week range is ₹650 to ₹1,230, reflecting substantial volatility over the past twelve months.
Chemfab’s market capitalization stands close to ₹1,130 crore, classifying it as a small-cap chemical manufacturer. The company specializes in basic inorganic chemicals and PVC-O pipes, mainly serving industries that require chlor alkali products.
Financially, recent results show net sales of about ₹92 crore for the March 2025 quarter, a year-on-year increase of roughly 12%. Despite this sales growth, profitability is under pressure, with negative trailing earnings; the latest EPS is around –₹4.8, resulting in a negative P/E ratio. The price-to-book ratio is almost 3, indicating the stock is priced at a premium to its book value. Return on capital employed and return on equity remain low, consistent with current profit margins.
In recent months, the stock’s price trend has been weak, down nearly 17% over six months and over 5% for the past three months, despite a near 7% rise in the last week. Liquidity and trade volumes are moderate and typical for its peer group.
Key risks include limited profit momentum, historically low return ratios, and high valuation multiples given the negative earnings. However, the company maintains a stable balance sheet, low financial leverage, and gradual growth in its core segment.
Chemfab Alkalis is best suited for investors interested in turnaround or deep value plays within the specialty chemicals sector, but caution is warranted because of volatile earnings and the stock’s premium to book value even amid operational challenges.
Chemfab’s market capitalization stands close to ₹1,130 crore, classifying it as a small-cap chemical manufacturer. The company specializes in basic inorganic chemicals and PVC-O pipes, mainly serving industries that require chlor alkali products.
Financially, recent results show net sales of about ₹92 crore for the March 2025 quarter, a year-on-year increase of roughly 12%. Despite this sales growth, profitability is under pressure, with negative trailing earnings; the latest EPS is around –₹4.8, resulting in a negative P/E ratio. The price-to-book ratio is almost 3, indicating the stock is priced at a premium to its book value. Return on capital employed and return on equity remain low, consistent with current profit margins.
In recent months, the stock’s price trend has been weak, down nearly 17% over six months and over 5% for the past three months, despite a near 7% rise in the last week. Liquidity and trade volumes are moderate and typical for its peer group.
Key risks include limited profit momentum, historically low return ratios, and high valuation multiples given the negative earnings. However, the company maintains a stable balance sheet, low financial leverage, and gradual growth in its core segment.
Chemfab Alkalis is best suited for investors interested in turnaround or deep value plays within the specialty chemicals sector, but caution is warranted because of volatile earnings and the stock’s premium to book value even amid operational challenges.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.